The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

25 Mar 2021 08:00

RNS Number : 4720T
4d Pharma PLC
25 March 2021
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BJL5BR07

Issuer Name

4D PHARMA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Merck Sharp & Dohme Corp

City of registered office (if applicable)

Whitehouse Station

Country of registered office (if applicable)

United States

4. Details of the shareholder

Is the shareholder the same as the person subject to the notification obligation, above?

Yes

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

23-Mar-2021

6. Date on which Issuer notified

23-Mar-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.650000

0.000000

4.650000

8315023

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

CLASS/TYPE OF SHARES ISIN CODE(IF POSSIBLE)

NUMBER OF DIRECT VOTING RIGHTS (DTR5.1)

NUMBER OF INDIRECT VOTING RIGHTS (DTR5.2.1)

% OF DIRECT VOTING RIGHTS (DTR5.1)

% OF INDIRECT VOTING RIGHTS (DTR5.2.1)

Ordinary Shares

8315023

0

4.650000

0.000000

Sub Total 8.A

8315023

4.650000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

TYPE OF FINANCIAL INSTRUMENT

EXPIRATION DATE

EXERCISE/CONVERSION PERIOD

NUMBER OF VOTING RIGHTS THAT MAY BE ACQUIRED IF THE INSTRUMENT IS EXERCISED/CONVERTED

% OF VOTING RIGHTS

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

TYPE OF FINANCIAL INSTRUMENT

EXPIRATION DATE

EXERCISE/CONVERSION PERIOD

PHYSICAL OR CASH SETTLEMENT

NUMBER OF VOTING RIGHTS

% OF VOTING RIGHTS

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate Controlling Person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Is there proxy voting?

No

Name of the proxy holder

 

The number and % of voting rights held

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

 

13. Place Of Completion

London United Kingdom

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFIFEDVSIEFIL
Date   Source Headline
9th Nov 20201:00 pmRNSSITC data MRx0518 monotherapy and combination
5th Nov 202012:00 pmRNSVirtual KOL Event SITC Data
30th Oct 20204:57 pmRNSHolding(s) in Company
23rd Oct 20201:17 pmRNSHolding(s) in Company
22nd Oct 20207:00 amRNSProposed Merger & Intention to seek NASDAQ Listing
14th Oct 202010:09 amRNSHolding(s) in Company
14th Oct 20207:00 amRNSPresentations on MRx0518 at SITC 2020
12th Oct 20202:01 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSTopline Results for Blautix phase II trial
30th Sep 20207:00 amRNSInterim Results
23rd Sep 20207:00 amRNSDirectorate Change
14th Sep 20204:30 pmRNSBlock Listing Six Monthly Return
7th Sep 20205:26 pmRNSHolding(s) in Company
1st Sep 20204:58 pmRNS4D hosts virtual R&D event
26th Aug 20207:00 amRNSMRx0158 Keytruda Part A clinical benefit data
14th Aug 20204:49 pmRNSHolding(s) in Company
12th Aug 20207:00 amRNSHolding(s) in Company
28th Jul 202010:34 amRNSHolding(s) in Company
24th Jul 20204:58 pmRNSHolding(s) in Company
20th Jul 20205:09 pmRNSHolding(s) in Company
16th Jul 20206:15 pmRNSHolding(s) in Company
16th Jul 20204:43 pmRNSHolding(s) in Company
15th Jul 20204:16 pmRNSHolding(s) in Company
13th Jul 20205:57 pmRNSResult of Fundraising
13th Jul 202012:13 pmRNSPlacing and Subscription of £7.7m
6th Jul 20207:00 amRNSOncology Clinical Update
2nd Jul 20204:02 pmRNSHolding(s) in Company
2nd Jul 20207:00 amRNSCOVID-19 study open for enrolment
30th Jun 20201:05 pmRNSResult of AGM
25th Jun 20207:00 amRNSHolding(s) in Company
22nd Jun 202011:19 amRNSHolding(s) in Company
10th Jun 20205:25 pmRNSHolding(s) in Company
10th Jun 20205:17 pmRNSHolding(s) in Company
10th Jun 202011:21 amRNSHolding(s) in Company
5th Jun 20201:00 pmRNSAnnual Report and Notice of AGM
5th Jun 20207:41 amRNS4D hosts virtual R&D event
26th May 20207:00 amRNSFinal Results
21st May 20207:00 amRNSDirectorate Change
19th May 20206:20 pmRNSHolding(s) in Company
12th May 20206:06 pmRNSHolding(s) in Company
11th May 20207:00 amRNSCompletion of immuno-oncology study safety phase
24th Apr 202011:30 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSPhase II study in COVID-19
17th Apr 20207:00 amRNSAppointment of Non-Executive Chairperson
17th Apr 20207:00 amRNSInterim analysis of Blautix phase II study data
30th Mar 202012:08 pmRNSSecond Price Monitoring Extn
30th Mar 202012:03 pmRNSPrice Monitoring Extension
19th Mar 20204:36 pmRNSPrice Monitoring Extension
19th Mar 20209:47 amRNSHolding(s) in Company
18th Mar 20204:44 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.